Question Covid-19 Cure ? A small study using Cancer Drug EXO-CD24 - phase 1 trials cure 29 of 30 severe to moderately infected patients in 3-5 days

Jul 2, 2020
236
27
130
Tel Aviv Sourasky Medical Center Successfully Completes Phase 1 Study:

29 out of 30 Moderate-to-Severe COVID-19 Patients Recover in 3 to 5 Days thanks to EXO-CD24

The thirtieth patient's symptoms also got better but outside of the five-day window, Israeli media claimed.



 
Feb 23, 2021
8
1
35
Kind of silly because no one knows any way to treat viruses, but the covid virus does no significant harm itself. The only problem is when the immune system over reacts, and there are hundreds of immuno suppressants that can help for that.
That is not a treatment, since an immune system over reaction is not a disease.
But there really is no reason for anyone to die, if treated in time with something that works for their immune system. And there is nothing that will work for everyone, since their immune systems are all going to be very different.
 
Jul 2, 2020
236
27
130
There are multiple treatments that have shown effectiveness at treating Covid-19 going back to the April to June 2020 time frame when the DoD tested various drugs to combat Covid-19 and came up with a range of alternatives some that were effective in hamsters both before and after Covid-19 infection - Amodiaquine

in April, tenOever’s funders at the US Defense Advanced Research Projects Agency asked him to run the Amodiaquine tests. “I was really reluctant to do it,” he says, “but we did eventually come to try.”

They gave Amodiaquine to hamsters in his lab, in early June, it offered considerable protection against the virus that causes Covid-19. They kept repeating it and seeing good results. The research team had already shown that, in human lung cells, the drug reduces levels of a harmless virus engineered to carry the same spike protein as the pandemic one. “It works beautifully,” Experiments on hamsters suggest that a amodiaquine holds some promise against the pandemic virus.

The surprising study became available on the preprint server bioRxiv on August 19. Its authors describe how they dosed a couple dozen hamsters with amodiaquine and then spritzed the rodents’ noses with the new coronavirus. The animals continued to receive amodiaquine for three more days, and then were checked against a control group that did not receive the drug. Hamsters treated with amodiaquine ended up with 70 percent less genetic material from the virus in their lungs.

In a second study, the researchers started healthy hamsters on amodiaquine, then put them in a cage with others that were sick. Again they did much better than their control-group counterparts: Treated animals ended up with 90 percent less viral material in their lungs.




But the research was sat on or sidelined

These treatments need to be researched and trialed by independent groups.

Drs and interest groups who are connected to or supported by big pharma funding, shares and positions dominate the Covid-19 decision making process and have been involved in medical trials while receiving funding from firms who are promoting expensive alternatives.

This is not discussed by the press and is clearly wrong and totally conflicted

Dr.Boulware, a key researcher and hydroxychlorquine / HQC skeptic should not have been conducting trials on HQC as he has conflicts of interest as he receives grants from Gilead the maunfacturer of Remdesivir which was a much more expensive alternative to HQC

The Minnesota study is one of a triad of randomized controlled trials, organized by Dr David Boulware, that aimed to test hydroxychloroquine’s efficacy for Covid-19; the trial failed.

Other trials were fully or partly successful but sidelined or ignored.

www.eventscribe.com/2019/IDWeek/fsPopup.asp?Mode=presenterInfo&PresenterID=688680

View: https://twitter.com/i/web/status/1284023642058301440








researchers at the University of Manchester, UK, reports on the compounds of interest that were identified as having potential for the treatment of COVID-19, from a library of almost 2,000 compounds from the APExBIO DiscoveryProbe library. Their findings have been released on the bioRxiv* preprint server.

This list of drugs includes Amodiaquine

Effective doses of these FDA-approved inhibitory compounds against the virus were found, indicating that they can reduce viral replication after infection. These compounds should be studied further to identify their place in managing COVID-19 patients.

Moreover, the study shows, interestingly, that some medications in use today may actually increase the susceptibility of the cells to infection


 

ASK THE COMMUNITY

Latest posts